JP2007532624A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007532624A5 JP2007532624A5 JP2007507862A JP2007507862A JP2007532624A5 JP 2007532624 A5 JP2007532624 A5 JP 2007532624A5 JP 2007507862 A JP2007507862 A JP 2007507862A JP 2007507862 A JP2007507862 A JP 2007507862A JP 2007532624 A5 JP2007532624 A5 JP 2007532624A5
- Authority
- JP
- Japan
- Prior art keywords
- active
- pharmaceutical composition
- pharmaceutically acceptable
- statin
- acetylcholinesterase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 11
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 11
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 10
- 208000024827 Alzheimer disease Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 3
- 229960005370 atorvastatin Drugs 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 229960003530 donepezil Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000000051 modifying effect Effects 0.000 claims 2
- 230000006641 stabilisation Effects 0.000 claims 2
- 238000011105 stabilization Methods 0.000 claims 2
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 claims 1
- 229940049950 atorvastatin 10 mg Drugs 0.000 claims 1
- 229960001770 atorvastatin calcium Drugs 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56214104P | 2004-04-14 | 2004-04-14 | |
| PCT/IB2005/000923 WO2005099823A1 (en) | 2004-04-14 | 2005-04-04 | Therapeutic combination for treatment of alzheimers disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007532624A JP2007532624A (ja) | 2007-11-15 |
| JP2007532624A5 true JP2007532624A5 (enExample) | 2008-05-15 |
Family
ID=34963723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007507862A Withdrawn JP2007532624A (ja) | 2004-04-14 | 2005-04-04 | アルツハイマー病の治療のための療法組合せ |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1737539A1 (enExample) |
| JP (1) | JP2007532624A (enExample) |
| KR (1) | KR20060133008A (enExample) |
| CN (1) | CN1960781A (enExample) |
| AU (1) | AU2005232447A1 (enExample) |
| BR (1) | BRPI0509881A (enExample) |
| CA (1) | CA2562069A1 (enExample) |
| IL (1) | IL178120A0 (enExample) |
| MX (1) | MXPA06011969A (enExample) |
| NO (1) | NO20065196L (enExample) |
| RU (1) | RU2006136361A (enExample) |
| TW (1) | TW200533341A (enExample) |
| WO (1) | WO2005099823A1 (enExample) |
| ZA (1) | ZA200608239B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI432195B (zh) * | 2007-10-03 | 2014-04-01 | Kowa Co | 神經細胞死亡抑制劑 |
| SI3413870T1 (sl) * | 2016-02-11 | 2021-12-31 | Sigmathera Sas | Igmezin za uporabo pri zdravljenju alzheimerjeve bolezni |
| MX2021015266A (es) * | 2019-06-14 | 2022-01-18 | Joshua O Atiba | Composicion farmaceutica triple para infecciones proteinaceas. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| ES2268393T3 (es) * | 2002-04-02 | 2007-03-16 | Janssen Pharmaceutica N.V. | Terapia con estatina para favorecer el mantenimiento de la funcion cognitiva. |
| WO2004034963A2 (en) * | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| JP2006512417A (ja) * | 2002-12-24 | 2006-04-13 | ニューロケム （インターナショナル） リミテッド | β−アミロイド関連疾患の治療のための治療用製剤 |
| WO2004071431A2 (en) * | 2003-02-05 | 2004-08-26 | Myriad Genetics, Inc. | Method and composition for treating neurodegenerative disorders |
| US20070110715A1 (en) * | 2003-03-19 | 2007-05-17 | Ares Trading S.A. | Treatment of alzheimer's disease |
| US20050090449A1 (en) * | 2003-05-13 | 2005-04-28 | Boehringer Ingelheim International Gmbh | Novel statine derivatives for the treatment of Alzheimer's disease |
-
2005
- 2005-04-04 JP JP2007507862A patent/JP2007532624A/ja not_active Withdrawn
- 2005-04-04 BR BRPI0509881-5A patent/BRPI0509881A/pt not_active IP Right Cessation
- 2005-04-04 KR KR1020067021174A patent/KR20060133008A/ko not_active Ceased
- 2005-04-04 CN CNA2005800173902A patent/CN1960781A/zh active Pending
- 2005-04-04 AU AU2005232447A patent/AU2005232447A1/en not_active Abandoned
- 2005-04-04 EP EP05718393A patent/EP1737539A1/en not_active Withdrawn
- 2005-04-04 MX MXPA06011969A patent/MXPA06011969A/es unknown
- 2005-04-04 RU RU2006136361/15A patent/RU2006136361A/ru not_active Application Discontinuation
- 2005-04-04 WO PCT/IB2005/000923 patent/WO2005099823A1/en not_active Ceased
- 2005-04-04 CA CA002562069A patent/CA2562069A1/en not_active Abandoned
- 2005-04-13 TW TW094111657A patent/TW200533341A/zh unknown
-
2006
- 2006-09-14 IL IL178120A patent/IL178120A0/en unknown
- 2006-10-03 ZA ZA200608239A patent/ZA200608239B/en unknown
- 2006-11-13 NO NO20065196A patent/NO20065196L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| FI2498756T4 (fi) | Neratinibimaleaatin tablettiformulaatiot | |
| RU2015107877A (ru) | Способы лечения болезни альцгеймера и фармацевтические композиции | |
| JP2009500443A5 (enExample) | ||
| EA200400664A1 (ru) | Фармацевтические композиции, включающие метформин и глибенкламид, применяемые для лечения сахарного диабета типа ii | |
| CO5390076A1 (es) | Composiciones farmaceuticas | |
| CA2671470A1 (en) | Powder formulation for valganciclovir | |
| WO2006116148A3 (en) | (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse | |
| JP2006514100A5 (enExample) | ||
| TW200722081A (en) | New therapeutic combinations for the treatment or prevention of depression | |
| RU2014129508A (ru) | Новая комбинация | |
| WO2008092072A3 (en) | Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof | |
| JP2006515299A5 (enExample) | ||
| RU2003100507A (ru) | Фармацевтические композиции | |
| EA201100430A1 (ru) | Стабильная комбинированная фармацевтическая композиция | |
| JP2009517411A5 (enExample) | ||
| WO2008062475A3 (en) | Pharmaceutical compositions of ursodiol | |
| JP2010523659A (ja) | スタチン類と抗肥満症薬との組み合わせ | |
| JP2007532624A5 (enExample) | ||
| JP2008503445A5 (enExample) | ||
| WO2007120930A3 (en) | Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives | |
| CA2633077A1 (en) | Solid-state form of amg 706 and pharmaceutical compositions thereof | |
| JP2007534731A5 (enExample) | ||
| TNSN07166A1 (en) | Composition comprising vlp and amyloid-beta peptide | |
| JP2005525391A5 (enExample) |